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ABSTRACT
Background: Acepromazine was found to reduce the incidence of vomiting induced by opioids such as morphine, hydro-
morphone and oxymorphone in dogs. Despite the effectiveness of the phenothiazine in preventing opioid-induced vomiting 
in this species, a single dose of acepromazine (0.05 mg/kg) was tested and the influence of dose on the antiemetic effect 
of the drug is unknown. The primary objective of this study was to evaluate the effect of three acepromazine doses on the 
incidence of vomiting induced by morphine in dogs. A secondary aim was to assess the degree of sedation and effects on 
physiological variables following administration of the combinations tested.
Materials, Methods & Results: All dogs received 0.5 mg/kg morphine (IM). Fifteen min before morphine, dogs in the 
Control, ACPLD, ACPMD and ACPHD groups were administered (IM) physiological saline or acepromazine at doses of 0.025, 
0.05 and 0.1 mg/kg, respectively. In Phase 1, purpose-bred dogs (n = 8) underwent each of the four treatments in a random-
ized, crossover design; the incidence of vomiting, sedation, pulse rate (PR), systolic, mean and diastolic blood pressures 
(SAP, MAP and DAP) were investigated for 60 min. Sedation was assessed by a numeric descriptive scale (NDS, range 
0-3) and a simple numerical scale (SNS, range 1-10). In Phase 2, client-owned dogs (n = 50) received a single treatment 
and only the incidence of vomiting was assessed. There was no significant difference between groups on the incidence of 
vomiting recorded in Phase 1, Phase 2 and the average of Phases 1 and 2. A significant decrease in PR was observed in 
most groups but no significant difference was detected between groups. Blood pressure decreased in all groups; during 
most of the evaluation period, SAP, MAP and DAP were significantly higher in the Control than in other treatments. Dogs 
in this study presented mild to intense sedation. A significant difference in NDS scores was observed between the Control 
and ACPMD groups whereas for SNS scores, significant differences were detected between the ACPMD and ACPHD groups 
compared with the Control group. The number of dogs presenting intense sedation as judged by the NDS (NDS score = 
3) were: 1/8, 3/8, 3/8 and 4/8 dogs in the Control, ACPLD, ACPMD and ACPHD groups, respectively.
Discussion: The hypothesis of the study was rejected. The acepromazine dose did not influence the frequency of morphine-
induced vomiting, the degree of sedation or cardiovascular variables after administration of either treatment. The frequency 
of vomiting was high (≥ 75%) in dogs of the present study regardless of the treatment administered. There was no significant 
difference in the frequency of vomiting in ACPLD, ACPMD and ACPHD as compared to the Control group. This finding was 
unexpected because it has been reported in a previous study that acepromazine reduced the incidence of opioid-induced 
vomiting in dogs. ACPLD, ACPMD and ACPHD improved the quality of sedation compared to the Control treatment but no 
significant difference in sedation scores was observed among these groups. These findings suggest that, when combined 
to morphine, there is no improvement in sedation when the acepromazine dose is increased above 0.025 mg/kg in dogs. 
Despite a significant decrease, mean values of PR, SAP, MAP and DAP remained within the physiological range for 
conscious dogs. In summary, none of the acepromazine doses was effective in preventing morphine-induced vomiting in 
dogs. Sedation is greater after acepromazine-morphine combinations than after morphine alone and is not influenced by 
the acepromazine dose. Cardiovascular effects induced by combinations administered in this study were well tolerated and 
of little clinical relevance to healthy conscious dogs.
Keywords: emesis, phenothiazine, neuroleptanalgesia, opioid, tranquilizer.
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INTRODUCTION
Opioid analgesics are the most commonly used 
drugs to provide intraoperative antinociception in dogs. 
These drugs can be combined with sedatives, such as 
acepromazine, to induce sedation and analgesia and such 
combinations have been named neuroleptanalgesia [12].
In dogs, acepromazine has been used in com-
bination with many opioids such as morphine [2,9,10], 
methadone [1,7,10], butorphanol [10], fentanyl, pe-
thidine [2], hydromorphone, oxymorphone [14] and 
tramadol [8,10].
In addition to the sedative effect, aceproma-
zine was also found to possess antiemetic properties. 
This feature may be of particular interest because 
acepromazine reduced the incidence of opioid-induced 
vomiting in dogs [14]. In one study, vomiting was ob-
served in 25% of dogs administered acepromazine 15 
min before morphine, whereas 75% of dogs vomited 
when no acepromazine was given before morphine 
[14]. The effectiveness of acepromazine in reducing 
the incidence of vomiting in dogs was also reported 
with the use of hydromorphone and oxymorphone 
[14]. Despite the effectiveness of the phenothiazine in 
preventing opioid-induced vomiting in dogs, a single 
dose of acepromazine (0.05 mg/kg) was tested and the 
influence of dose on the antiemetic effect of the drug 
is unknown.
The primary objective of this study was to 
evaluate the effect of three acepromazine doses on the 
incidence of vomiting induced by morphine in dogs. A 
secondary aim was to assess the degree of sedation and 
effects on physiological variables following adminis-
tration of the combinations tested. The hypothesis was 
that the effects of acepromazine would be dose related. 
MATERIALS AND METHODS
Study design
This was a 2-phase study. In Phase 1, the 
effects of acepromazine on the incidence of morphine-
-induce vomiting, sedation and physiological variables 
were investigated in purpose-bred dogs (n = 8). Each 
dog underwent four treatments in a randomized, 
crossover design.
In Phase 2, client-owned dogs (n = 50) received 
a single treatment and only the incidence of morphine-
-induced vomiting was assessed. Brachycephalic dog 
breeds were excluded from the study.
Drug treatments
Each treatment consisted of two intramuscular 
injections in pelvic limbs. The first injection for the 
control treatment was 0.025 mL/kg of physiological sa-
line. For the ACPLD, ACPMD and ACPHD treatments, the 
first injection consisted of acepromazine (Acepran®)1 at 
doses of 0.025, 0.05 and 0.1 mg/kg, respectively. For 
all treatment groups, 0.5 mg/kg morphine (Dimorf®)2 
was administered for the second injection. On all 
occasions, 15 min were allowed between the first and 
second injections.
Phase 1
Eight adult, mongrel, purpose-bred dogs (7 
females and 1 male) were used in Phase 1. Weight of 
the dogs was 14.9 ± 3.6 kg (mean ± SD). Dogs were 
judged to be healthy based on physical examination 
and laboratorial findings (CBC and serum chemis-
try). Food but not water was withheld for 12 h prior 
to experiments. Each of 8 dogs was administered the 
control, ACPLD, ACPMD and ACPHD treatments, on 
different occasions, in a randomized crossover design 
with 1-week washout intervals. 
Variables recorded included pulse rate (PR), 
systolic, mean and diastolic blood pressures (SAP, 
MAP and DAP), degree of sedation, and frequency 
of vomiting. An oscillometric device (petMAP®)3 
was used to assess PR, SAP, MAP and DAP. The cuff 
bladder was chosen according to the manufacturer re-
commendations and was positioned above the carpus. 
Five consecutive readings were obtained on each time 
point and the average was taken for analysis. Sedation 
was assessed by use of a numeric descriptive scale 
(NDS) and a simple numerical scale (SNS). The NDS 
ranged from 0 to 3, as follows: 0, no sedation; 1, mild 
sedation, less alert but still active; 2, moderate sedation, 
drowsy, recumbent but can walk; 3, intense sedation, 
very drowsy, unable to walk [9,14]. The SNS consisted 
of a scale ranging from 0 to 10 where 0 represents no 
sedation and 10 represents the most sedation possible 
[2]. For both the NDS and SNS, only whole numbers 
could be assigned. Two observers, unaware of the 
assigned treatment, were responsible for scoring se-
dation. On each occasion, the scores were recorded 
after consensus between the observers. Sedation scores, 
PR, SAP, MAP and DAP were recorded before admi-
nistration of any drug (baseline), 15 min after the first 
injection (time point 15), and 15, 30 and 45 min after 
the second injection (time points 30, 45 and 60 min).
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After administration of morphine (second 
injection), the dogs were observed during 15 min for 
the occurrence of vomiting. Vomiting was defined as 
vigorous abdominal contractions followed by attempts 
to expel gastric contents, even if nothing has yet been 
expelled. The time elapsed until vomiting was recorded.
Phase 2
Thirty two client-owned dogs scheduled for 
diagnostic or surgical procedures needing sedation or 
general anesthesia were enrolled in Phase 2. All owners 
gave their informed consent. Dogs were classified as 
ASA physical status I or II. These 32 dogs were ran-
domly assigned to receive a single treatment (control, 
ACPLD, ACPMD or ACPHD). After administration of 
the experimental treatment, occurrence of vomiting 
within 15 min after the second injection (morphine) 
was registered. Other variables evaluated in Phase 1 
experiments were not recorded in Phase 2.
Anesthetic records for other 18 female dogs 
that had participated in another research study were 
also included in Phase 2. All of the 18 dogs were 
administered 0.5 mg/kg morphine intramuscularly 
as premedication before an ovariohysterectomy and 
had the occurrence of vomiting recorded in anesthetic 
records. Data from these 18 dogs were included in the 
control group.
Statistical analysis 
Data distribution was checked by the Shapiro-
-Wilk test. Differences among groups in the frequency 
of vomiting were compared by a Chi-square test. 
Weight and age of dogs, and time until first vomiting 
episode were compared by a Kruskal-Wallis and a 
Dunn’s multiple comparison test. In Phase 1, compari-
sons of sedation scores among groups were performed 
with a Friedman test and a Dunn’s multiple compa-
rison test. The same approach was used to compare 
sedation scores after administration of injections with 
baseline values. For parametric data (PR, SAP, MAP 
and DAP), differences among groups were analyzed 
with a two-way repeated measures analysis of variance 
(ANOVA) and a Bonferroni correction for multiple pai-
rwise comparisons. For comparisons over time within 
a group (versus baseline values), a one way repeated 
measures ANOVA and a Dunnett post hoc test were 
performed. For all analyses, a P value of < 0.05 was 
considered significant.
RESULTS
Phase 1
The frequency of vomiting and time until first 
vomiting episode are summarized in Table 1. There 
were no significant differences between groups.
A significant decrease in PR was observed in 
the control and ACPHD groups at selected time points. 
In the ACPLD and ACPMD groups, PR decreased nume-
rically but not significantly. There was no significant 
difference between groups in PR throughout the ex-
periments (Table 2). In the control group, MAP and 
DAP decreased bellow baseline values from 15 to 45 
min whereas SAP did not change significantly over 
time. In the ACPLD, ACPMD and ACPHD groups, SAP, 
MAP and DAP were lower than baseline values from 
15 to 60 min. During most of the evaluation period, 
SAP, MAP and DAP were significantly higher in the 
control than in other treatments (Table 2).
One dog in the control treatment did not 
develop evidence of sedation (NDS score = 0). All 
other dogs in the control and remaining treatments 
presented mild to intense sedation. In the control group, 
Table 1. Times until first vomiting episode and number of dogs that 
vomited after intramuscular administration of 0.5 mg/kg morphine 
(Phases 1 and 2 of the study). Fifteen min before morphine, dogs in 
the Control, ACPLD, ACPMD and ACPHD groups were administered 
(IM) physiological saline or acepromazine at doses of 0.025, 0.05 
and 0.1 mg/kg, respectively. 
Time until 
vomiting (min)
Number of dogs 
that vomited (%)
Phase 1
Control 3 ± 1 8/8 (100%)
ACPLD 3 ± 1 8/8 (100%)
ACPMD 3 ± 0 6/8 (75%)
ACPHD 4 ± 1 6/8 (75%)
Phase 2
Control 3 ± 2 19/24 (79%)
ACPLD 4 ± 1 6/9 (67%)
ACPMD 3 ± 1 9/12 (75%)
ACPHD 3 ± 1 5/5 (100%)
Phases 1 + 2
Control 3 ± 2 27/32 (84%)
ACPLD 3 ± 1 14/17 (82%)
ACPMD 3 ± 1 15/20 (75%)
ACPHD 4 ± 1 11/13 (85%)
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NDS and SNS scores were significantly greater than 
baseline at 30, 45 and 60 min. In the ACPLD, ACPMD 
and ACPHD groups, NDS and SNS scores were signi-
ficantly increased above baseline from 15 to 60 min 
(Table 3). For comparisons among groups in NDS 
scores, a significant difference was observed between 
the control and ACPMD groups (at 15 and 30 min). 
For SNS scores, significant differences were detected 
between the ACPMD and ACPHD groups compared with 
the control group at selected time points (Table 3). The 
number of dogs presenting intense sedation as judged 
by the NDS (NDS score = 3) were: 1/8, 3/8, 3/8 and 
4/8 dogs in the control, ACPLD, ACPMD and ACPHD 
groups, respectively.
Phase 2
A total of 50 dogs were enrolled in Phase 2. 
Demographic data for these dogs are presented in Table 
4. There was no significant difference between groups 
for weight and age of dogs. There was no significant 
difference between groups in the frequency of vomiting 
and time elapsed until first vomiting episode.
DISCUSSION
The hypothesis of the study was rejected. The 
acepromazine dose did not influence the frequency of 
morphine-induced vomiting, the degree of sedation 
or cardiovascular variables after administration of 
either treatment.
The frequency of vomiting was high (≥ 75%) 
in dogs of the present study regardless of the treatment 
administered. There was no significant difference in the 
frequency of vomiting in acepromazine-treated groups 
(ACPLD, ACPMD and ACPHD) as compared to the control 
group. This finding was unexpected. In a previous study 
in dogs, the overall frequency of opioid-induced vomi-
ting was reduced from 55% to 18% when acepromazine 
(0.05 mg/kg, IM) was administered 15 min before 
morphine, oxymorphone or hydromorphone [14]. In 
the same study, the frequency of vomiting was 25% 
when acepromazine was administered 15 min before 
morphine, compared to 75% when no acepromazine 
was administered before the opioid [14]. The incidence 
of morphine-induced vomiting when no acepromazine 
was administered before morphine was similar in the 
Table 2. Mean ± SD values for pulse rate (PR), systolic (SAP), mean (MAP) and diastolic (DAP) pressure in 8 dogs used in Phase 1. 
All dogs received 0.5 mg/kg morphine intramuscularly. Fifteen min before morphine, dogs in the Control, ACPLD, ACPMD and ACPHD 
groups were administered (IM) physiological saline or acepromazine at doses of 0.025, 0.05 and 0.1 mg/kg, respectively. Timepoint 15 
was registered 15 minutes after saline or acepromazine and before morphine. Timepoints 30, 45 and 60 are after morphine administration.
Baseline 15 30 45 60
PR
(beats/min)
Control 123 ± 16a 103 ± 14a* 103 ± 24a 99 ± 21a* 98 ± 28a*
ACPLD 116 ± 19a 112 ± 20a 95 ± 21a 93 ± 42a 98 ± 52a
ACPMD 121 ± 18a 113 ± 18a 96 ± 18a 102 ± 36a 106 ± 46a
ACPHD 123 ± 18a 115 ± 19a 96 ± 28a* 90 ± 23a* 88 ± 29a*
SAP
(mmHg)
Control 162 ± 24ab 146 ± 15a 148 ± 18a 151 ± 19a 150 ± 24a
ACPLD 165 ± 11a 132 ± 18ab* 122 ± 17b* 116 ± 16b* 120 ± 16b*
ACPMD 144 ± 13b 123 ± 26b* 123 ± 13b* 120 ± 15b* 119 ± 14b*
ACPHD 164 ± 25a 134 ± 10ab* 122 ± 20b* 112 ± 12b* 111 ± 13b*
MAP
(mmHg)
Control 117 ± 16a 102 ± 7a* 101 ± 14a* 103 ± 15a* 106 ± 16a
ACPLD 118 ± 7a 90 ± 11ab* 86 ± 12b* 82 ± 13b* 83 ± 11b*
ACPMD 104 ± 13b 86 ± 12b* 85 ± 6b* 84 ± 11b* 85 ± 15b*
ACPHD 110 ± 15ab 92 ± 8ab* 86 ± 15b* 80 ± 11b* 77 ± 9b*
DAP
(mmHg)
Control 89 ± 12ab 79 ± 7a* 78 ± 15a* 77 ± 12a* 81 ± 12a
ACPLD 95 ± 9a 69 ± 10ab* 67 ± 12ab* 63 ± 12b* 65 ± 12b*
ACPMD 83 ± 13b 66 ± 9b* 65 ± 6b* 64 ± 10b* 67 ± 14b*
ACPHD 91 ± 14ab 75 ± 10ab* 66 ± 11b* 62 ± 8b* 60 ± 8b*
Within a column, values with one superscript in common do not differ significantly (P < 0.05). *Within a row, represents significant difference from 
baseline (P < 0.05).
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Table 3. Median (interquartile range) sedation scores for the numeric descriptive scale (NDS) and simple numerical scale (SNS) in 
8 dogs used in Phase 1. All dogs received 0.5 mg/kg morphine intramuscularly. Fifteen min before morphine, dogs in the Control, 
ACPLD, ACPMD and ACPHD groups were administered (IM) physiological saline or acepromazine at doses of 0.025, 0.05 and 0.1 mg/
kg, respectively. Timepoint 15 was registered 15 min after saline or acepromazine and before morphine. Timepoints 30, 45 and 60 are 
after morphine administration.
Baseline 15 30 45 60
NDS
Control 0.0 (0.0-0.0)a 0.0 (0.0-0.8)a 1.0 (0.3-2.0)*a 1.5 (1.0-2.0)*a 2.0 (1.0-2.0)*a
ACPLD 0.0 (0.0-0.0)a 1.0 (0.2-2.0)*ab 1.0 (1.0-2.7)*ab 2.0 (1.0-2.7)*a 2.0 (1.0-3.0)*a
ACPMD 0.0 (0.0-0.0)a 2.0 (1.2-2.0)*b 2.0 (2.0-2.7)*b 2.0 (2.0-3.0)*a 2.0 (2.0-3.0)*a
ACPHD 0.0 (0.0-0.0)a 1.0 (1.0-2.0)*ab 1.5 (1.0-3.0)*ab 2.5 (1.0-3.0)*a 2.5 (1.2-3.0)*a
SNS
Control 0.0 (0.0-0.0)a 0.0 (0.0-1.5)a 2.0 (0.5-3.7)*a 3.0 (1.2-5.2)*a 3.5 (2.2-5.5)*a
ACPLD 0.0 (0.0-0.0)a 2.0 (0.2-4.0)*ab 4.0 (3.2-6.7)*ab 6.5 (4.0-8.0)*ab 6.5 (4.0-8.0)*ab
ACPMD 0.0 (0.0-0.0)a 2.5 (1.2-4.0)*ab 5.0 (4.0-6.0)*b 6.0 (5.2-6.7)*ab 6.0 (6.0-7.5)*ab
ACPHD 0.0 (0.0-0.0)a 2.5 (2.0-3.7)*b 4.5 (4.0-7.5)*b 6.0 (4.0-8.5)*b 7.0 (5.2-8.5)*b
Within a column, values with one superscript in common do not differ significantly (P < 0.05). *Within a row, represents significant difference from 
baseline (P < 0.05).
Table 4. Demographic data for 50 dogs included in Phase 2. Values for weight and age are presented as mean ± SD (range). All dogs 
received 0.5 mg/kg morphine intramuscularly. Fifteen min before morphine, dogs in the Control, ACPLD, ACPMD and ACPHD groups were 
administered (IM) physiological saline or acepromazine at doses of 0.025, 0.05 and 0.1 mg/kg, respectively.
Breed Sex Body weight (kg) Age (months)
Control (n = 24) Crossbreed (n = 13)
Poodle (n = 3)
Beagle (n = 2)
Bull Terrier (n = 1)
Chow Chow (n = 1)
Cocker Spaniel (n = 1)
German Spitz (n = 1)
Dachshund (n = 1)
Yorkshire Terrier (n = 1)
M (n = 3)
F (n = 21)
11.2 ± 5.5
(4.5-23.7)
41 ± 42
(5-144)
ACPLD (n = 9) Crossbreed (n = 6)
Golden Retriever (n = 1)
Labrador Retriever (n = 1)
Poodle (n = 1)
M (n = 4)
F (n = 5)
17.8 ± 13.1
(2.6-44.7)
47 ± 32
(7-108)
ACPMD (n = 12) Crossbreed (n = 4)
Poodle (n = 3)
Pinscher (n = 2)
Labrador Retriever (n = 1)
German Shepherd Dog (n = 1)
German Spitz (n = 1)
M (n = 5)
F (n = 7)
12.1 ± 10.4
(2.5-33.5)
45 ± 36
(8-120)
ACPHD (n = 5) Maltese (n = 1)
Belgian Shepherd (n = 1)
Poodle (n = 1)
Crossbreed (n = 1)
Dachshund (n = 1)
M (n = 3)
F (n=2)
12.1 ± 11.1
(6.5-31.1)
65 ± 35
(12-96)
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present study (control group = 84%) and the other 
study (75%) [14]. However, when acepromazine was 
administered 15 min before morphine, a much higher 
incidence of vomiting was observed in our study 
(82%, 75% and 85%, in the ACPLD, ACPMD and ACPHD 
groups) compared to the 25% value observed in the 
previous study [14].
Two reasons may have contributed for the 
discrepancies between this and the previous study: a) 
fasting period; and b) definition of vomiting. Food but 
not water was withheld for 12 h in the present study. 
No information about fasting was found in the study 
by Valverde et al. [14] in 2004. A longer fasting period 
and/or water deprivation might contribute to decrease 
the incidence of vomiting. In our study, abdominal con-
tractions followed by attempts to expel gastric contents 
were considered as vomiting episodes even if nothing 
had been expelled. In the other study, retching and 
vomiting were evaluated separately [14]. It is possible 
that some vomiting episodes in our study might be con-
sidered as retching episodes in the previous study [14].
The sedative effect induced by acepromazine-
-opioid combinations has been extensively studied 
in dogs [2,4,7,9,10,13]. To the authors’ knowledge, 
this is the first study to report the influence of dose 
of the phenothiazine on the sedating action of the 
combination. In the present study, ACPLD, ACPMD and 
ACPHD improved the quality of sedation compared to 
the control treatment, although a significant difference 
from controls was only detected for the ACPMD and 
ACPHD treatments. No difference in sedation scores 
was observed among the ACPLD, ACPMD and ACPHD 
treatments. These findings suggest that, when combi-
ned to morphine, there is no improvement in sedation 
when the acepromazine dose is increased above 0.025 
mg/kg in dogs.
Cardiovascular adverse effects observed in 
this study were decreased PR (control and ACPHD 
treatments) and decreased blood pressure (most nota-
bly in the ACPLD, ACPMD and ACPHD treatments). The 
decrease in PR is likely the result of opioid-induced 
increase in parasympathetic tone [5]. The reduction 
in blood pressure is most likely associated to acepro-
mazine administration. It has been proposed that the 
blockade of alpha-1 adrenergic receptors at vascular 
beds results in vasodilation and consequently, decre-
ase in arterial blood pressure [6,11]. In the present 
study, no significant differences in SAP, MAP or DAP 
were detected among the ACPLD, ACPMD and ACPHD 
treatments. These findings indicate that the effect 
of acepromazine on blood pressure of conscious-
-sedated dogs is not influenced by the dose of the 
phenothiazine. Despite a significant decrease, mean 
values of PR, SAP, MAP and DAP remained within 
the physiological range for conscious dogs [3].
One limitation of this study was the inclusion 
of data records from 18 dogs of another research 
study in Phase 2. The inclusion of this data prevented 
randomization of the treatment, as all 18 dogs were 
included in the control group. As a result, more dogs 
were assigned to the control group than other groups 
in Phase 2. Although the authors consider this a limita-
tion of the study, we believe that the inclusion of data 
from these 18 dogs had little influence on the overall 
frequency of vomiting in the control group. The inci-
dence of vomiting was high in all groups in Phases 1 
and 2 of the study.
CONCLUSION 
In summary, none of the acepromazine doses 
was effective in preventing morphine-induced vomiting 
in dogs. Sedation is greater after acepromazine-mor-
phine combinations than after morphine alone and is 
not influenced by the acepromazine dose. Cardiovascu-
lar effects induced by drugs administered in this study 
were well tolerated and of little clinical relevance to 
healthy conscious dogs.
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